ShockWave Medical (SWAV) Stock Forecast, Price Target & Predictions
SWAV Stock Forecast
ShockWave Medical stock forecast is as follows: an average price target of $258.17 (represents a -22.88% downside from SWAV’s last price of $334.75) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.
SWAV Price Target
The average price target for ShockWave Medical (SWAV) is $258.17 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $360.00 to $175.00. This represents a potential -22.88% downside from SWAV's last price of $334.75.
SWAV Analyst Ratings
According to 10 Wall Street analysts, ShockWave Medical's rating consensus is 'Hold'. The analyst rating breakdown for SWAV stock is 0 'Strong Buy' (0.00%), 1 'Buy' (10.00%), 8 'Hold' (80.00%), 1 'Sell' (10.00%), and 0 'Strong Sell' (0.00%).
ShockWave Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 05, 2024 | William Plovanic | Johnson Rice | $335.00 | $325.48 | 2.92% | 0.07% |
| Apr 02, 2024 | Adam Maeder | Piper Sandler | $360.00 | $320.51 | 12.32% | 7.54% |
| Jan 06, 2023 | Morgan Stanley | $224.00 | $208.17 | 7.60% | -33.08% | |
| Aug 29, 2022 | Piper Sandler | $338.00 | $304.44 | 11.02% | 0.97% | |
| Aug 09, 2022 | Morgan Stanley | $255.00 | $258.93 | -1.52% | -23.82% | |
| Aug 09, 2022 | Wells Fargo | $255.00 | $221.77 | 14.98% | -23.82% | |
| Aug 09, 2022 | Piper Sandler | $278.00 | $221.77 | 25.36% | -16.95% | |
| Jul 15, 2022 | Morgan Stanley | $201.00 | $209.90 | -4.24% | -39.96% | |
| May 10, 2022 | Morgan Stanley | $180.00 | $133.39 | 34.94% | -46.23% | |
| May 10, 2022 | Wells Fargo | $176.00 | $115.91 | 51.84% | -47.42% | |
| May 10, 2022 | Leerink Partners | $175.00 | $115.91 | 50.98% | -47.72% | |
| May 10, 2022 | Adam Maeder | Piper Sandler | $245.00 | $115.91 | 111.37% | -26.81% |
| Mar 03, 2022 | Travis Steed | Bank of America Securities | $200.00 | $178.22 | 12.22% | -40.25% |
The latest ShockWave Medical stock forecast, released on Apr 05, 2024 by William Plovanic from Johnson Rice, set a price target of $335.00, which represents a 2.92% increase from the stock price at the time of the forecast ($325.48), and a 0.07% increase from SWAV last price ($334.75).
ShockWave Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $347.50 |
| Last Closing Price | $334.75 | $334.75 | $334.75 |
| Upside/Downside | -100.00% | -100.00% | 3.81% |
In the current month, the average price target of ShockWave Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ShockWave Medical's last price of $334.75. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 09, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Apr 08, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Apr 08, 2024 | Johnson Rice | Market Perform | Neutral | Downgrade |
| Apr 05, 2024 | Johnson Rice | Hold | Market Perform | Downgrade |
| Apr 05, 2024 | Johnson Rice | Hold | Downgrade | |
| Apr 05, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| Apr 05, 2024 | Needham | Buy | Hold | Downgrade |
| Apr 04, 2024 | Wolfe Research | Peer Perform | Downgrade | |
| Mar 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 24, 2023 | Needham | Buy | Buy | Hold |
| Jul 10, 2023 | Itau BBA | Underperform | Downgrade | |
| Jul 10, 2023 | Barclays | Equal-Weight | Upgrade | |
| Jul 10, 2023 | Citigroup | Sell | Downgrade | |
| Jul 10, 2023 | Keefe, Bruyette & Woods | Market Perform | Downgrade | |
| Jul 10, 2023 | Wells Fargo | Equal-Weight | Underweight | Downgrade |
| Jul 10, 2023 | RBC Capital | Sector Perform | Downgrade | |
| Jul 10, 2023 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| Jan 06, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Dec 12, 2022 | Wells Fargo | Overweight | Equal-Weight | Downgrade |
| Aug 09, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 09, 2022 | Wells Fargo | Overweight | Overweight | Hold |
| Aug 09, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 15, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 10, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 10, 2022 | Wells Fargo | Overweight | Overweight | Hold |
| May 10, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Feb 18, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Feb 18, 2022 | SVB Leerink | Outperform | Outperform | Hold |
ShockWave Medical's last stock rating was published by Wells Fargo on May 09, 2024. The company gave SWAV a "Equal-Weight" rating, the same as its previous rate.
ShockWave Medical Financial Forecast
ShockWave Medical Revenue Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $202.98M | - | - | $161.07M | $144.03M | - | - | $93.63M | $84.18M | - | - | $31.90M | $22.72M | - | - | $15.20M | $14.31M | - |
| Avg Forecast | $371.09M | $337.78M | $325.77M | $299.21M | $312.84M | $287.07M | $278.96M | $256.28M | $253.19M | $232.20M | $227.06M | $207.67M | $199.43M | $184.72M | $173.84M | $147.30M | $143.18M | $123.96M | $107.51M | $86.41M | $75.43M | $61.21M | $45.22M | $29.90M | $20.16M | $14.68M | $8.35M | $14.17M | $13.47M | $10.43M |
| High Forecast | $371.09M | $337.78M | $325.77M | $299.21M | $312.84M | $287.07M | $278.96M | $256.28M | $253.19M | $232.20M | $230.18M | $207.68M | $200.00M | $187.99M | $173.84M | $147.30M | $143.18M | $123.96M | $107.51M | $86.41M | $75.43M | $61.21M | $45.22M | $29.90M | $20.16M | $14.68M | $8.35M | $14.17M | $13.47M | $10.43M |
| Low Forecast | $371.09M | $337.78M | $325.77M | $299.21M | $312.84M | $287.07M | $278.96M | $256.28M | $253.19M | $232.20M | $225.28M | $207.66M | $199.10M | $182.70M | $173.84M | $147.30M | $143.18M | $123.96M | $107.51M | $86.41M | $75.43M | $61.21M | $45.22M | $29.90M | $20.16M | $14.68M | $8.35M | $14.17M | $13.47M | $10.43M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | - | - | 1.09% | 1.01% | - | - | 1.08% | 1.12% | - | - | 1.07% | 1.13% | - | - | 1.07% | 1.06% | - |
ShockWave Medical's average Quarter revenue forecast for Mar 24 based on 3 analysts is $207.67M, with a low forecast of $207.66M, and a high forecast of $207.68M. SWAV's average Quarter revenue forecast represents a 2.31% increase compared to the company's last Quarter revenue of $202.98M (Dec 23).
ShockWave Medical EBITDA Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $46.36M | - | - | $41.37M | $45.62M | - | - | $16.73M | $15.02M | - | - | $-22.12M | $-296.87K | - | - | $-17.68M | $-13.85M | - |
| Avg Forecast | $-110.63M | $-100.70M | $-97.12M | $-89.20M | $-93.27M | $-85.59M | $-83.17M | $-76.40M | $-75.48M | $-69.23M | $-67.70M | $18.68M | $-59.46M | $-55.07M | $-51.83M | $16.98M | $42.47M | $-36.96M | $-32.05M | $15.44M | $-22.49M | $-18.25M | $-13.48M | $-11.90M | $-6.01M | $-4.38M | $-2.49M | $-14.07M | $-4.02M | $-3.11M |
| High Forecast | $-110.63M | $-100.70M | $-97.12M | $-89.20M | $-93.27M | $-85.59M | $-83.17M | $-76.40M | $-75.48M | $-69.23M | $-67.17M | $22.42M | $-59.36M | $-54.47M | $-51.83M | $20.38M | $50.97M | $-36.96M | $-32.05M | $18.53M | $-22.49M | $-18.25M | $-13.48M | $-9.52M | $-6.01M | $-4.38M | $-2.49M | $-11.26M | $-4.02M | $-3.11M |
| Low Forecast | $-110.63M | $-100.70M | $-97.12M | $-89.20M | $-93.27M | $-85.59M | $-83.17M | $-76.40M | $-75.48M | $-69.23M | $-68.62M | $14.94M | $-59.63M | $-56.05M | $-51.83M | $13.59M | $33.98M | $-36.96M | $-32.05M | $12.35M | $-22.49M | $-18.25M | $-13.48M | $-14.27M | $-6.01M | $-4.38M | $-2.49M | $-16.89M | $-4.02M | $-3.11M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.78% | - | - | 2.44% | 1.07% | - | - | 1.08% | -0.67% | - | - | 1.86% | 0.05% | - | - | 1.26% | 3.45% | - |
3 analysts predict SWAV's average Quarter EBITDA for Mar 24 to be $18.68M, with a high of $22.42M and a low of $14.94M. This is -59.70% lower than ShockWave Medical's previous annual EBITDA (Dec 23) of $46.36M.
ShockWave Medical Net Income Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $44.30M | - | - | $39.13M | $140.91M | - | - | $14.52M | $12.94M | - | - | $-23.60M | $-15.87K | - | - | $-18.77M | $-14.74M | - |
| Avg Forecast | $79.75M | $71.53M | $68.63M | $61.49M | $68.60M | $62.06M | $59.63M | $54.59M | $58.07M | $49.69M | $45.16M | $16.21M | $34.25M | $29.98M | $31.87M | $14.74M | $36.61M | $25.72M | $17.06M | $13.40M | $3.28M | $-2.19M | $-15.33M | $-12.69M | $-16.30M | $-21.28M | $-23.91M | $-14.94M | $-19.73M | $-19.62M |
| High Forecast | $79.75M | $71.53M | $68.63M | $61.49M | $68.60M | $62.06M | $59.63M | $54.59M | $58.07M | $49.69M | $55.07M | $19.45M | $43.55M | $36.81M | $31.87M | $17.68M | $43.93M | $25.72M | $17.06M | $16.08M | $3.28M | $-2.19M | $-15.33M | $-10.15M | $-16.30M | $-21.28M | $-23.91M | $-11.95M | $-19.73M | $-19.62M |
| Low Forecast | $79.75M | $71.53M | $68.63M | $61.49M | $68.60M | $62.06M | $59.63M | $54.59M | $58.07M | $49.69M | $42.59M | $12.97M | $30.90M | $24.29M | $31.87M | $11.79M | $29.29M | $25.72M | $17.06M | $10.72M | $3.28M | $-2.19M | $-15.33M | $-15.23M | $-16.30M | $-21.28M | $-23.91M | $-17.93M | $-19.73M | $-19.62M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.29% | - | - | 2.66% | 3.85% | - | - | 1.08% | 3.94% | - | - | 1.86% | 0.00% | - | - | 1.26% | 0.75% | - |
ShockWave Medical's average Quarter net income forecast for Mar 24 is $16.21M, with a range of $12.97M to $19.45M. SWAV's average Quarter net income forecast represents a -63.41% decrease compared to the company's last Quarter net income of $44.30M (Dec 23).
ShockWave Medical SG&A Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $92.06M | - | - | $73.22M | $60.38M | - | - | $48.35M | $42.82M | - | - | $31.22M | $23.07M | - | - | $16.64M | $14.05M | - |
| Avg Forecast | $271.80M | $247.41M | $238.61M | $219.16M | $229.14M | $210.26M | $204.32M | $187.71M | $185.45M | $170.07M | $166.31M | $53.97M | $146.07M | $135.29M | $127.33M | $49.07M | $121.12M | $90.80M | $78.75M | $44.61M | $55.25M | $44.83M | $33.12M | $16.79M | $14.76M | $10.75M | $6.11M | $13.24M | $9.87M | $7.64M |
| High Forecast | $271.80M | $247.41M | $238.61M | $219.16M | $229.14M | $210.26M | $204.32M | $187.71M | $185.45M | $170.07M | $168.60M | $64.77M | $146.49M | $137.70M | $127.33M | $58.88M | $145.34M | $90.80M | $78.75M | $53.53M | $55.25M | $44.83M | $33.12M | $20.15M | $14.76M | $10.75M | $6.11M | $15.89M | $9.87M | $7.64M |
| Low Forecast | $271.80M | $247.41M | $238.61M | $219.16M | $229.14M | $210.26M | $204.32M | $187.71M | $185.45M | $170.07M | $165.01M | $43.18M | $145.83M | $133.82M | $127.33M | $39.25M | $96.90M | $90.80M | $78.75M | $35.68M | $55.25M | $44.83M | $33.12M | $13.43M | $14.76M | $10.75M | $6.11M | $10.59M | $9.87M | $7.64M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.63% | - | - | 1.49% | 0.50% | - | - | 1.08% | 0.78% | - | - | 1.86% | 1.56% | - | - | 1.26% | 1.42% | - |
ShockWave Medical's average Quarter SG&A projection for Mar 24 is $53.97M, based on 3 Wall Street analysts, with a range of $43.18M to $64.77M. The forecast indicates a -41.37% fall compared to SWAV last annual SG&A of $92.06M (Dec 23).
ShockWave Medical EPS Forecast
| Dec 26 | Oct 26 | Jul 26 | Mar 26 | Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 4 | 3 | 6 | 10 | 5 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $1.16 | - | - | $1.07 | $3.89 | - | - | $0.41 | $0.37 | - | - | $-0.68 | $-0.00 | - | - | $-0.59 | $-0.49 | - |
| Avg Forecast | $2.07 | $1.86 | $1.78 | $1.60 | $1.78 | $1.61 | $1.55 | $1.42 | $1.51 | $1.29 | $1.17 | $0.99 | $0.89 | $0.78 | $0.83 | $0.79 | $1.01 | $0.67 | $0.44 | $0.18 | $0.09 | $-0.06 | $-0.40 | $-0.45 | $-0.42 | $-0.55 | $-0.62 | $-0.49 | $-0.51 | $-0.51 |
| High Forecast | $2.07 | $1.86 | $1.78 | $1.60 | $1.78 | $1.61 | $1.55 | $1.42 | $1.51 | $1.29 | $1.43 | $0.99 | $1.13 | $0.96 | $0.83 | $0.79 | $1.01 | $0.67 | $0.44 | $0.18 | $0.09 | $-0.06 | $-0.40 | $-0.45 | $-0.42 | $-0.55 | $-0.62 | $-0.49 | $-0.51 | $-0.51 |
| Low Forecast | $2.07 | $1.86 | $1.78 | $1.60 | $1.78 | $1.61 | $1.55 | $1.42 | $1.51 | $1.29 | $1.11 | $0.99 | $0.80 | $0.63 | $0.83 | $0.79 | $1.01 | $0.67 | $0.44 | $0.18 | $0.09 | $-0.06 | $-0.40 | $-0.45 | $-0.42 | $-0.55 | $-0.62 | $-0.49 | $-0.51 | $-0.51 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.30% | - | - | 1.35% | 3.86% | - | - | 2.23% | 4.34% | - | - | 1.52% | 0.00% | - | - | 1.20% | 0.96% | - |
According to 3 Wall Street analysts, ShockWave Medical's projected average Quarter EPS for Mar 24 is $0.99, with a low estimate of $0.99 and a high estimate of $0.99. This represents a -14.72% decrease compared to SWAV previous annual EPS of $1.16 (Dec 23).
ShockWave Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| OM | Outset Medical | $1.01 | $3.00 | 197.03% | Buy |
| TMDX | TransMedics Group | $65.71 | $116.33 | 77.04% | Buy |
| TNDM | Tandem Diabetes Care | $34.23 | $51.43 | 50.25% | Buy |
| DXCM | DexCom | $77.80 | $104.50 | 34.32% | Buy |
| INSP | Inspire Medical Systems | $190.71 | $223.17 | 17.02% | Buy |
| ALGN | Align | $228.81 | $264.17 | 15.45% | Buy |
| NARI | Inari Medical | $56.16 | $64.00 | 13.96% | Buy |
| SYK | Stryker | $370.81 | $408.33 | 10.12% | Buy |
| EW | Edwards Lifesciences | $74.12 | $76.33 | 2.98% | Buy |
| PODD | Insulet | $263.35 | $268.00 | 1.77% | Buy |
| MASI | Masimo | $174.07 | $168.33 | -3.30% | Buy |
| PEN | Penumbra | $247.55 | $230.25 | -6.99% | Buy |
| CLPT | ClearPoint Neuro | $16.34 | $15.00 | -8.20% | Buy |